PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D change of 6.82% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-13.19%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-2.45%
Operating expenses reduction while Biotechnology median is 6.86%. Seth Klarman would investigate advantages.
-2.45%
Total costs reduction while Biotechnology median is 8.54%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-13.13%
EBITDA decline while Biotechnology median is -2.18%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses change of 49.45% versus flat Biotechnology. Walter Schloss would verify control.
10.71%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS change of 23.59% versus flat Biotechnology. Walter Schloss would verify quality.
23.59%
Diluted EPS change of 23.59% versus flat Biotechnology. Walter Schloss would verify quality.
16.70%
Share count reduction below 50% of Biotechnology median of 0.01%. Jim Chanos would check for issues.
16.70%
Diluted share change of 16.70% versus stable Biotechnology. Walter Schloss would verify approach.